Prolactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: a review

Nenhuma Miniatura disponível
Data
2016
Autores
Brandao, Denise Froes [UNIFESP]
Strasser-Weippl, Kathrin
Goss, Paul E.
Orientadores
Tipo
Revisão
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Hyperprolactinemia, defined as a sustained elevation of prolactin (PRL) levels greater than 530 mIU/L in women and greater than 424 mIU/L in men, has been implicated for a long time in breast cancer etiology and prognosis. Elevated PRL values (approximately 2-3 times higher than the reference values) are a common adverse effect of antipsychotic medications, especially with first-generation drugs, and most antipsychotics carry a standard warning regarding PRL elevations on their US product labels. These associations foster undertreatment of serious psychiatric illnesses in both otherwise healthy patients and cancer patients. This review assesses both the preclinical and clinical evidence that has led to the hypothesis of PRL's role in breast cancer risk or breast cancer progression. It is concluded that taken together, the published data are unconvincing and insufficient to deprive cancer patients in general and breast cancer patients specifically of potentially effective antipsychotic or antidepressant medications for serious psychiatric indications. We thus call on revised medication guidelines to avoid the existing undertreatment of serious psychiatric illnesses among cancer patients based on an unproven contraindication to psychiatric medications. Cancer 2016;122:184-188. (c) 2015 American Cancer Society. This review discusses the evidence for a role of hyperprolactinemia in breast cancer risk and prognosis. New guidelines are needed for antipsychotic and antidepressant medications among cancer patients.
Descrição
Citação
Cancer. Hoboken, v. 122, n. 2, p. 184-188, 2016.
Coleções